2025-10-29 14:31:52
Presenters: Dumbuya H,1 Alexis A,2 Lynch S,3 Callender V,4 Desai SR,5 Draelos ZD6
Affiliations: 1La Roche-Posay Laboratoire Dermatologique, L'Oreal USA, New York, NY; 2Department of Dermatology, Weill Cornell Medicine, New York, NY; 3L’Oréal USA Research and Innovation, Clark, NJ; 4Callender Dermatology and Cosmetic Center, Glenn Dale, MD; 5Innovative Dermatology, Plano, TX; 6Dermatology Consulting Services, PLLC, High Point, NC
Background: Variations in the clinical presentation of skin aging between racial/ ethnic populations have been reported.1 Compared to their White counterparts, individuals with skin of color (SOC), with Fitzpatrick phototype IV and above, generally show fewer visible sign of wrinkles and fine lines.2 Due to higher levels of melanin in their skin, SOCs are more susceptible to experiencing dyschromia (hyper- and hypo-pigmentation), leading to uneven skin tone, ashy skin and blotchiness.1 Despite skin discoloration being considered as one of the top dermatological concerns for SOCs, they remain underrepresented in clinical trials focused on skin-aging prevention and photoprotection.3
Objectives: In this study, we evaluated the efficacy of an innovative serum and sunscreen regimen containing 2-MNG, an ingredient that quenches melanin precursors, on improving facial dyschromia in women of color following 12 weeks of usage.
Methods: A total of 60 female subjects completed study from diverse racial/ethnic backgrounds, aged 25 to 70 years old with skin phototypes IV-VI, and presenting with mild to moderate uneven skin tone, hyperpigmentation, and skin roughness. After completing a 1-week washout period, all subjects started using a 2-MNG -containing product regimen, consisting of a serum (applied morning and evening) and a sunscreen SPF 30 (applied 15min before sun exposure) for 12 weeks. Evaluations included clinical assessments, quality-of-life questionnaires, plus clinical imaging at several time points.
Results: After 2 weeks of using the 2-MNG-containing product regimen (serum & SPF30), dermatological assessments showed significant improvement in skin brightness and radiance, plus overall skin appearance in all subjects. Starting at Week 4, we clinically observed significant reduction in hyperpigmentation, dyschromia, plus photodamage overtime. Interestingly, clinical expert grading and imaging also demonstrated significant improvement in skin smoothness, fine lines, and pores appearances. By Week 12, all subjects perceived a significant improvement in quality-of-life: from feeling less embarrassed and unattractive to decreasing the use of camouflage to cover up skin discoloration-related concerns.
Conclusions: In summary, our results demonstrate that a 2-MNG-containing product regimen, consisting of a serum and sunscreen SPF30, can effectively improve overall skin tone and quality in patients of color with facial dyschromia-related concerns. The significant improvement in overall quality-of-life experienced by clinical participants after using product regimen overtime may help support clinicians on skin-aging prevention and photoprotection strategies to consider for all patients, particularly for patients of color.
Disclosures: HD is an employee of La Roche-Posay Laboratoire Dermatologique, L’Oreal USA. SL is an employee of L’Oréal USA Research and Innovation. Dr. AA is a researcher and consultant for L’Oreal.
Funding: This work was supported by La Roche-Posay Laboratoire Dermatologique US.
References:
1 Venkatesh S, Maymone MBC, Vashi NA, et al. Aging in skin of color. Clin Dermatol. 2019 Jul-Aug;37(4):351-357.
2 Campiche R, Trevisan S, Séroul P, et al. Appearance of aging signs in differently pigmented facial skin by a novel imaging system. J Cosmet Dermatol. 2019 Apr;18(2):614-627.
3 Callender VD, Harvey VM, Hartman CL, et al. Do Women with Skin of Color Think They Are Well Represented in Skin Aging Prevention Information? J Clin Aesthet Dermatol. 2024 Apr;17(4):18-22.
©Matrix Medical Communications. View All Articles.